Literature DB >> 18324424

Mesangial hypercellularity in children: presenting features and outcomes.

Douglas M Silverstein1, Randall D Craver.   

Abstract

Mesangial hypercellularity (MH), in the absence of sclerosis or immune deposition, was a common finding on renal biopsy in our center. We studied 66 children with predominant MH. Among all patients older than 2.7 years, blood pressure (BP) percentile and glomerular filtration rate (GFR) remained stable. Serum albumin (Alb) trended higher (3.0+/-0.2 start vs. 3.4+/-0.2 end g/dl, p=0.06) and urine protein/creatinine lower (4.2+/-0.9 start vs. 2.3+/-0.9 end mg/mg, p=0.18) at the end of the study period. The proportion with stage 1 CKD remained constant: 94% start vs. 92% end. At end, Alb was lower in patients referred for nephrotic syndrome (NS): 4.4+/-0.3 hematuria vs. 4.2+/-0.2 proteinuria vs. 2.8+/-0.3 NS g/dl, p<0.05 vs. both. Alb was lower (p=0.03) and urine protein/creatinine trended higher in patients with diffuse foot-process fusion (FPF). Twenty-five percent of patients with focal FPF developed NS, all had relapses, and 63% were steroid sensitive (SS). All but one with diffuse FPF presented with NS; 86% had relapses (mean 1 year) and 63% were SS. GFR trended higher at the end in those with matrix thickening (mat) (119.6+/-4.7 no mat vs. 129.1+/-2.6 mat ml/min per 1.73 m2, p=0.1). Those without mat were less SS (59% no mat vs. 80% mat) and were more likely to require alkylating agents (Alk) for NS. Among those with positive immunofluorescence (IF), 82% had immunoglobulin M (IgM) alone; those with positive IF were more SS and needed Alk for NS. MH predicts a favorable prognosis. FPF predicts NS and multiple relapses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18324424     DOI: 10.1007/s00467-008-0750-0

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  22 in total

Review 1.  Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease.

Authors:  Yasuhisa Kurogi
Journal:  Med Res Rev       Date:  2003-01       Impact factor: 12.944

2.  Localization of matrix metalloproteinases and their inhibitors in experimental progressive kidney scarring.

Authors:  A K Ahmed; J L Haylor; A M El Nahas; T S Johnson
Journal:  Kidney Int       Date:  2007-02-07       Impact factor: 10.612

Review 3.  Aberrant glycosylation in IgA nephropathy (IgAN).

Authors:  Rosanna Coppo; Alessandro Amore
Journal:  Kidney Int       Date:  2004-05       Impact factor: 10.612

4.  Nephrotic syndrome associated with diffuse mesangial hypercellularity: is it a heterogeneous disease entity?

Authors:  K Joh; N Matsuyama; Y Kanetsuna; N Usui; M Hattori; W Yumura; S Aizawa
Journal:  Am J Nephrol       Date:  1998       Impact factor: 3.754

Review 5.  Relationship between proteinuria and epithelial cell changes in minimal lesion glomerulopathy.

Authors:  H R Powell
Journal:  Nephron       Date:  1976       Impact factor: 2.847

Review 6.  The glomerular mesangial cell: an expanding role for a specialized pericyte.

Authors:  D Schlondorff
Journal:  FASEB J       Date:  1987-10       Impact factor: 5.191

7.  Foot process fusion and glomerular filtration rate in minimal change nephrotic syndrome.

Authors:  S O Bohman; G Jaremko; A B Bohlin; U Berg
Journal:  Kidney Int       Date:  1984-04       Impact factor: 10.612

8.  Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy?

Authors:  S V McLennan; D J Kelly; M Schache; M Waltham; V Dy; R G Langham; D K Yue; R E Gilbert
Journal:  Kidney Int       Date:  2007-06-06       Impact factor: 10.612

9.  Immune deposits and mesangial hypercellularity in minimal change nephrotic syndrome: clinical relevance.

Authors:  W R Allen; L B Travis; T Cavallo; B H Brouhard; R J Cunningham
Journal:  J Pediatr       Date:  1982-02       Impact factor: 4.406

10.  Monocyte adhesion to mesangial matrix modulates cytokine and metalloproteinase production.

Authors:  Ravinder S Chana; John Martin; Enam U Rahman; David C Wheeler
Journal:  Kidney Int       Date:  2003-03       Impact factor: 10.612

View more
  5 in total

1.  Long-term outcome of idiopathic steroid-resistant nephrotic syndrome in children: response to comments.

Authors:  Aya Inaba; Yuko Hamasaki; Kenji Ishikura; Tetsuji Kaneko
Journal:  Pediatr Nephrol       Date:  2015-12-01       Impact factor: 3.714

Review 2.  C1q nephropathy in the pediatric population: pathology and pathogenesis.

Authors:  Scott E Wenderfer; Rita D Swinford; Michael C Braun
Journal:  Pediatr Nephrol       Date:  2010-02-24       Impact factor: 3.714

3.  Do C1q or IgM nephropathies predict disease severity in children with minimal change nephrotic syndrome?

Authors:  Mateja Vintar Spreitzer; Alenka Vizjak; Dušan Ferluga; Rajko B Kenda; Tanja Kersnik Levart
Journal:  Pediatr Nephrol       Date:  2013-07-13       Impact factor: 3.714

4.  APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis.

Authors:  Jarcy Zee; Michelle T McNulty; Jeffrey B Hodgin; Olga Zhdanova; Sangeeta Hingorani; Jonathan Ashley Jefferson; Keisha L Gibson; Howard Trachtman; Alessia Fornoni; Katherine M Dell; Heather N Reich; Serena Bagnasco; Larry A Greenbaum; Richard A Lafayette; Debbie S Gipson; Elizabeth Brown; Matthias Kretzler; Gerald Appel; Kamalanathan K Sambandam; Katherine R Tuttle; Dhruti Chen; Meredith A Atkinson; Marie C Hogan; Frederick J Kaskel; Kevin E Meyers; John O'Toole; Tarak Srivastava; Christine B Sethna; Michelle A Hladunewich; J J Lin; Cynthia C Nast; Vimal K Derebail; Jiten Patel; Suzanne Vento; Lawrence B Holzman; Ambarish M Athavale; Sharon G Adler; Kevin V Lemley; John C Lieske; Jonathan J Hogan; Crystal A Gadegbeku; Fernando C Fervenza; Chia-Shi Wang; Raed Bou Matar; Pamela Singer; Jeffrey B Kopp; Laura Barisoni; Matthew G Sampson
Journal:  Pediatr Nephrol       Date:  2021-03-01       Impact factor: 3.714

5.  IgM exacerbates glomerular disease progression in complement-induced glomerulopathy.

Authors:  Sarah E Panzer; Jennifer Laskowski; Brandon Renner; Liudmila Kulik; Danica Ljubanovic; Kendra M Huber; Weixiong Zhong; Matthew C Pickering; V Michael Holers; Joshua M Thurman
Journal:  Kidney Int       Date:  2015-05-06       Impact factor: 10.612

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.